Currently out of the existing stock ratings of Timur Ivannikov, 16 are a BUY (88.89%), 2 are a HOLD (11.11%).

Timur Ivannikov

Work Performance Price Targets & Ratings Chart

Analyst Timur Ivannikov, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 80.95% that have a potential upside of 36.57% achieved within 313 days.

Timur Ivannikov’s has documented 29 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RCKT, Rocket Pharmaceuticals at 05-May-2023.

Wall Street Analyst Timur Ivannikov

Analyst best performing recommendations are on NE (NOBLE PLC).
The best stock recommendation documented was for NE (NOBLE PLC) at 11/15/2021. The price target of $21 was fulfilled within 11 days with a profit of $1.13 (5.11%) receiving and performance score of 4.64.

Average potential price target upside

CBIO Catalyst Biosciences NEXI Neximmune ANAB AnaptysBio RCKT Rocket Pharmaceuticals KYMR Kymera Therapeutics LPTX Leap Therapeutics NE Noble plc

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Mar-2026

$22

$3.44 (18.53%)

$25

4 months 6 days ago
(02-Mar-2026)

2/2 (100%)

$10.8 (96.43%)

152

Buy Since 25-Jun-2025

$32

$13.44 (72.41%)

$28

7 months 4 days ago
(04-Dec-2025)

0/3 (0%)

$19.01 (146.34%)

Buy Since 14-Jul-2025

$27

$8.44 (45.47%)

11 months 24 days ago
(14-Jul-2025)

0/1 (0%)

$14.2 (110.94%)

Buy Since 12-Nov-2021

$400

4 years 3 months 7 days ago
(31-Mar-2022)

1/1 (100%)

$204.75 (104.87%)

459

Hold

4 years 7 months 21 days ago
(16-Nov-2021)

1/1 (100%)

$-14.38 (-43.08%)

196

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Timur Ivannikov?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?